article thumbnail

California Enters Insulin Manufacturing: Can We Expect to See a California Effect?

Bill of Health

Once approved by the FDA, CalRx insulin will be made available at $30 to all Californians who need it. Increased access to drug pricing data can inform innovation policy decisions on exclusivities, competition, and access for the pharmaceutical industry in general. Insulin is the first product the initiative will manufacture.

article thumbnail

Health Provider News – February 18, 2022

Hall Render

13-year Medicare payment dispute will return to HHS, court rules. Meet new FDA chief Dr. Robert Califf: 5 things to know. Outpatient push being felt in architecture industry. A layoff list, expired medicine, neglected patients: Illinois hospital loses Medicare contract. CMS delays star ratings update until July.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Prescription Drugs: From Costs and Bad Reputation to Civica Rx and Amazon to the Rescue

Health Populi

health consumers believe that Medicare should be allowed to negotiate with drug companies to fetch lower prices for prescription drugs, and that more drugs should switch to generic when possible. consumers have long-ranked the pharmaceutical industry relatively low, but above car salespeople and the Federal government.

article thumbnail

Pharma – 2023 Health IT Predictions

Healthcare IT Today

This could be a breakthrough for the pharmaceutical industry. Lauren Ohlsson, Lead of Industry Solutions – Pharmaceuticals & Healthcare at VDX.tv. In 2023, PLD (Physician Level Data) reporting from digital media partners will become increasingly essential to pharmaceutical organizations.

article thumbnail

Health Provider News

Hall Render

NATIONAL 6 health systems using GPT and AI tools 100,000 nurses left industry during the pandemic, report finds AHA backs bill to delay Medicaid DSH cuts by 2 years AHA launches info hub for healthcare quality leaders AHA opposes MedPAC recommendations to Congress on site-neutral, Part B drug, wage index policies AHA ramps up 340B protection efforts (..)